Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.